Return on Retained Earnings (RORE) is an indicator of a company's growth potential, it shows how much a company earns by reinvesting its retained earnings, i.e. profits after dividend payments.
Ekso Bionics Holdings's 3-Year RORE % for the quarter that ended in Mar. 2026 was -33.48%.
The industry rank for Ekso Bionics Holdings's 3-Year RORE % or its related term are showing as below:
EKSO's 3-Year RORE % is ranked worse than 75.16% of 777
companies
in the Medical Devices & Instruments industry
Industry Median: -4.03
vs EKSO: -33.48
Return on Retained Earnings (RORE) is important to investors because it reveals a company's efficiency and growth potential. A higher RORE indicates a higher return. A high RORE indicates that the company should reinvest profits into the business. A lower RORE suggests that the company should distribute profits to shareholders by paying out dividends, since those dollars aren't generating much additional growth for the company.
There are a several different ways to arrive at the Return on Retained Earnings. The simplest way to calculate it is by using published information on Earnings per Share (EPS) and Dividend per Share (DPS) over a selected period. Here, 3-year period is chosen.
Be Aware
Please keep in mind that the RORE is relative to the nature of the business and its competitors. If another company in the same sector is producing a lower return on retained earnings, it doesn’t necessarily mean it’s a bad investment. It may just suggest the company is older and no longer in a high growth stage. At such a stage in the business cycle, it would be expected to see a lower RORE and higher dividend payout.
Ekso Bionics Holdings 3-Year RORE % Related Terms
Ekso Bionics Holdings 3-Year RORE % Historical Data
* Premium members only.
The historical data trend for Ekso Bionics Holdings's 3-Year RORE % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
EKSO vs POCI, HBIO, NEPH: 3-Year RORE % Comparison
For the Medical Instruments & Supplies subindustry, Ekso Bionics Holdings's 3-Year RORE %, along with its competitors' market caps and 3-Year RORE % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Ekso Bionics Holdings 3-Year RORE % vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Ekso Bionics Holdings's 3-Year RORE % distribution charts can be found below:
* The bar in red indicates where Ekso Bionics Holdings's 3-Year RORE % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
In the calculation of 3-Year RORE %, the most recent and first period EPS (Diluted) is the trailing twelve months (TTM) data ended in Mar. 2026 and 3-year before.
Ekso Bionics Holdings (EKSO) has a 3-Year RORE % of -33.48 as of Mar. 2026. 3-Year RORE % shows how much a company earns by reinvesting its retained earnings in 3-year. View historical data on Ekso Bionics Holdings and its competitors. According to the industry distribution chart, Ekso Bionics Holdings ranks #584 out of 777 companies in the Medical Devices & Instruments industry, placing it in the top 75.2%.
Is Ekso Bionics Holdings' 3-Year RORE % too high?
Ekso Bionics Holdings' current 3-Year RORE % is -33.48. Based on the distribution chart, Ekso Bionics Holdings ranks #584 out of 777 companies in the Medical Devices & Instruments industry, which is in the bottom quartile relative to peers. Overall, Ekso Bionics Holdings has a GF Score™ of 32/100, reflecting its overall financial health beyond just this single metric.
How does Ekso Bionics Holdings' 3-Year RORE % compare to POCI and HBIO?
According to the Medical Devices & Instruments industry distribution chart, Ekso Bionics Holdings ranks #584 out of 777 companies for 3-Year RORE %. This places Ekso Bionics Holdings in the lower half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 3-Year RORE % for a Medical Devices & Instruments company?
A good 3-Year RORE % depends on the Medical Devices & Instruments industry context. However, 3-Year RORE % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 3-Year RORE % mean?
A high 3-Year RORE % can signal that a stock is expensive relative to its fundamentals. 3-Year RORE % shows how much a company earns by reinvesting its retained earnings in 3-year. View historical data on Ekso Bionics Holdings and its competitors. Ekso Bionics Holdings's current 3-Year RORE % is -33.48. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Ekso Bionics Holdings stock overvalued right now?
Ekso Bionics Holdings (EKSO) has a current 3-Year RORE % of -33.48. The stock's GF Value™ is $4.40, compared to a current price of $11.65 — trading 164.8% above its estimated fair value. The current 3-Year RORE % is -33.48. Ekso Bionics Holdings' overall GF Score™ is 32/100 with 10 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 3-Year RORE % calculated?
3-Year RORE % is calculated from a company's financial statements. For Ekso Bionics Holdings (EKSO), the current 3-Year RORE % is -33.48 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Ekso Bionics Holdings (EKSO) Overvalued in 2026?
Based on GuruFocus' analysis, Ekso Bionics Holdings stock appears to be overvalued.
The current stock price of $11.65 is trading 164.8% above its estimated GF Value™ of $4.40.
Key valuation signals for EKSO:
3-Year RORE %: -33.48
GF Value™: $4.40 vs. price of $11.65 (164.8% above fair value)
No single metric tells the full story. See the EKSO stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Ekso Bionics Holdings Inc designs, develops and sells exoskeleton technology used in healthcare and industrial markets. The wearable exoskeletons are to be worn over clothes and controlled by a trained operator to augment human strength, endurance, and mobility. The company's segments are Enterprise Health and Personal Health. All of the company's operations are held in the United States. The regions the company operates in are the Americas, EMEA, and APAC.
32GF Score
Get the complete analysis for EKSO
3-Year RORE % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
EKSO has been successfully added to your 
